BioCentury | Sep 19, 2019
Tools & Techniques

Atomwise's JV spree

...biotech is developing inhibitors of epigenetic regulator KDM5B that reactivate expression of tumor suppressor protein HEXIM1...
...a driver of Angelman's syndrome. Targets UBE3A (E6AP) - Ubiquitin protein ligase E3A HEXIM1 - Hexamethylene bis-acetamide inducible 1...
BioCentury | Dec 9, 2013
Company News

Hexim Pharmaceuticals, Laboratoires Bailleul, Sinclair IS Pharma sales and marketing update

Sinclair said it divested non-core products Effederm , Xclair , Salinum and Numoisyn ( SST ) for £1.1 million ($1.8 million) in cash. Laboratoires Bailleul acquired acne treatment Effederm, which had £300,000 ($485,910) in revenues for the year ended...
BioCentury | Oct 18, 2012
Distillery Therapeutics

Indication: Musculoskeletal disease

...Hexim1+/- mice had greater muscle regeneration following injury than wild-type controls. In wild-type mice, transplanted Hexim1+/...
...regeneration than transplanted wild-type satellite cells. Next steps could include screening for compounds that reduce HEXIM1...
Items per page:
1 - 3 of 3